ZymoGenetics
Template:Short description {{#invoke:Infobox|infobox}}Template:Template otherTemplate:Main other{{#invoke:Check for clobbered parameters|check|nested=1|template=Infobox company|cat=Template:Main other|name; company_name|logo; company_logo|logo_alt; alt|trade_name; trading_name|former_names; former_name|type; company_type|predecessors; predecessor|successors; successor|foundation; founded|founders; founder|defunct; dissolved|hq_location; location|hq_location_city; location_city|hq_location_country; location_country|num_locations; locations|areas_served; area_served|net_income; profit|net_income_year; profit_year|owners; owner |homepage; website }}{{#invoke:Check for unknown parameters|check|unknown=Template:Main other|preview=Page using Template:Infobox company with unknown parameter "_VALUE_" | ignoreblank=y | alt | area_served | areas_served | assets | assets_year | aum | brands | company_logo | company_name | company_type | defunct | dissolved | divisions | embed | equity | equity_year | fate | footnotes | former_name | former_names | foundation | founded | founder | founders | genre | homepage | hq_location | hq_location_city | hq_location_country | incorporated | image | image_alt | image_caption | image_size | image_upright | income_year | industry | ISIN | key_people | location | location_city | location_country | locations | logo | logo_alt | logo_caption | logo_class | logo_size | logo_upright | members | members_year | module | name | native_name | native_name_lang | net_income | net_income_year | num_employees | num_employees_year | num_locations | num_locations_year | operating_income | owner | owners | parent | predecessor | predecessors | production | production_year | products | profit | profit_year | rating | ratio | revenue | revenue_year | romanized_name | services | subsid | successor | successors | traded_as | trade_name | trading_name | type | website| qid | fetchwikidata | suppressfields | noicon | nocat | demo | categories }}
ZymoGenetics, Inc was one of the oldest biotechnology/pharmaceutical companies in the USA,<ref name="New York Times-ZymoGenetics Will Become Independent of Novo Nordisk" /> based in Seattle, Washington. The company was involved in the development of therapeutic proteins. Located on Lake Union, the address of the ZymoGenetics headquarters was 1201 Eastlake Avenue East.<ref name="Homepage-ZymoGenetics, a Bristol-Myers Squibb Company">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> It was closed in 2019 after its acquisition by Bristol Myers Squibb.<ref name="closure1">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="closure2">Template:Cite news</ref>
The company was founded in 1981<ref name="Xconomy- Bristol-Myers Squibb to Stay in Seattle, Keep ZymoGenetics Workers">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> by Professors Earl W. Davie and Benjamin D. Hall of the University of Washington and 1993 Nobel Laureate in Chemistry Michael Smith of the University of British Columbia.<ref name="Homepage-ZymoGenetics, a Bristol-Myers Squibb Company" /> Initially named Zymos,<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> the company was forced to change its name to ZymoGenetics under threat of trademark infringement from the similarly named semiconductor company ZyMOS.<ref>Template:Citation</ref> Soon after its founding, ZymoGenetics began working on recombinant proteins with Danish company Novo Nordisk, and was acquired by that company in 1988.<ref name="Novo Nordisk completes divestment of ZymoGenetics, Inc.">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> It was spun off as a public company in 2000.<ref name="New York Times-ZymoGenetics Will Become Independent of Novo Nordisk">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Bristol-Myers Squibb acquired the company in 2010 for $885 million.<ref name="BMS forges $885M deal to buy ZymoGenetics">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>Template:Cite news</ref>
ZymoGenetics' headquarters was previously in the landmark Lake Union Steam Plant building.<ref>Template:Cite news</ref> This structure was built from 1914 to 1921 by Seattle City Light, the municipal electric utility.<ref name="Xconomy- What Will Happen to ZymoGenetics' Landmark Headquarters when Bristol Calls the Shots?">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> At the time, the building was in poor condition with many broken windows; Bruce Carter, the chief executive at the time, described it as "the mother of all fixer-uppers".<ref>Template:Cite news</ref> In December 2016, ZymoGenetics announced that they would not renew the lease to the Steam Plant building, due to expire in 2019;<ref name="NotRenewingLease">Template:Cite news</ref> the Fred Hutchinson Cancer Research Center later moved into it.<ref>Template:Cite news</ref> At the time, ZymoGenetics did not plan on closing its Bothell manufacturing site;<ref name="NotRenewingLease" /> however, it was sold to Seattle Genetics in August 2017.<ref>Template:Cite news</ref> ZymoGenetics closed completely in 2019.<ref name="closure1" /><ref name="closure2" />
Corporate governanceEdit
In late 2013, the company's president, Stephen W. Zaruby, left and took up the president and chief executive officer roles at Aurinia Pharmaceuticals.<ref name="slatko2013">Template:Cite magazine</ref>